Vaccine composition for mucosal administration

A vaccine composition and mucosal administration technology, applied in the directions of vaccines, drug combinations, drug delivery, etc., can solve the problems of giving difficult medical workers acupuncture accident patients, heat-labile enterotoxin, etc., and avoid acupuncture infection. Risk of accident, improvement of quality of life, effect of improved efficiency

Inactive Publication Date: 2014-08-06
NITTO DENKO CORP
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, injections have the following problems: pain, fear, injection scars and scars developed from injection scars, only medical workers can perform injections, intradermal injections with high immune effects are difficult to administer, and there are needles for medical workers. It cannot be said to be the best route of administration because of the risk of infection accidents, the need to go to the hospital frequently when repeated administration is a burden on the patient's life, and the generation of medical waste that requires special disposal such as injection needles.
As an adjuvant studied in immunization by means other than injection, for example, by transdermal administration or transmucosal administration, aluminum salts such as aluminum hydroxide, aluminum phosphate, and aluminum chloride are listed; cholera toxin, Escherichia coli Toxins such as heat-resistant enterotoxin, etc., but not yet in use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition for mucosal administration
  • Vaccine composition for mucosal administration
  • Vaccine composition for mucosal administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0149] Liquid formulations administered sublingually

[0150] Liquid formulations having the compositions shown in Tables 1 to 9 below were produced and used as administration samples for mouse immunization tests. Specifically, 20 parts by weight of an additive (DMSO) and physiological saline as a base were added to the compounding amounts of antigenic peptides and cellular immunity induction promoters described in Tables 1 to 9, and a desired pharmacologically acceptable acid, The total amount was 100 parts by weight, and mixed to prepare a liquid preparation for sublingual administration.

[0151] GPC3 peptide, survivin 2B peptide, HER2 / neu_A24 peptide, MAGE3_A24 peptide, IPEP87 peptide, HER2 / neu E75 peptide, PR1 peptide, HER2 / neu_A02 peptide, MAGE3_A02 peptide, HBVenv peptide, and Peptide-25 were chemically synthesized using HPLC Refined products. OVA protein was purchased from Sigma-Aldrich.

[0152] Imiquimod was purchased from Tokyo Chemical Industry. Cyclic di-GMP (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug.

Description

technical field [0001] The present invention relates to vaccine compositions for mucosal administration. Background technique [0002] Vaccines that are widely used generally administer pathogens such as microorganisms or viruses or parts thereof in order to induce immunity. In addition, there are cancer vaccines, the purpose of which is to enable the cellular immune system to recognize cancer cell-specific antigens, thereby inducing a specific attack on cancer cells through the immune system, which is used as one of the means of cancer treatment. [0003] Usually, the invasion of microorganisms, viruses, due to their size, is prevented by the skin, therefore, vaccines need to be administered invasively into the body. Thus, immunization usually uses injections. However, injections have the following problems: pain, fear, injection scars and scars developed from injection scars, only medical workers can perform injections, intradermal injections with high immune effects are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K9/00
CPCA61K39/0011A61K39/39A61K2039/542A61K2039/55511A61K2039/55516A61K2039/55561A61K2039/55566A61K2039/55583A61K2039/572A61P31/12A61P35/00A61P37/00A61P37/04A61K39/001106A61K39/00115A61K39/00117A61K39/001186A61K2039/80A61K38/08A61K38/10A61K48/00
Inventor 冈崎有道松下恭平浅利大介宍户卓矢前田佳己大久保胜之李文婧堀光彦杉山治夫
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products